drugset / Trial / NCT00806208
Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)
RandomizedSingle-groupOpen-labelTreatment
Summary
A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
Timeline
- Start
- 1999-01
- Primary completion
- 2000-01
- Completion
- 2000-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Siplizumab | Monoclonal antibody | 0.012 mg/kg | — |
| Comparator | Siplizumab | Monoclonal antibody | 0.04 mg/kg | — |
| Comparator | Siplizumab | Monoclonal antibody | 0.12 mg/kg | — |
| Comparator | Siplizumab | Monoclonal antibody | 0.4 mg/kg | — |